Evidence map›Paper›PMID 41172996›Full record

ArticleCell reports. Medicine2025

Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling.

Pavlos Msaouel, Nizar M Tannir, Funda Meric-Bernstam, Jennifer M King, Martin H Voss, Jessica P Cheng, Susan S Thomas, Zita D Lim, Menuka Karki, Rong He and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Renal Medullary Carcinoma: Utility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Pavlos MsaouelDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA. Electronic address: pmsaouel@mdanderson.org.
Nizar M TannirDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jennifer M KingDivision of Hematology-Oncology, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA.
Martin H VossDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jessica P ChengDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Susan S ThomasDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zita D LimDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Menuka KarkiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Rong HeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Giannicola GenoveseDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rahul A ShethDepartment of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Davis R IngramDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Diana ShamsutdinovaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Khalida M WaniDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei-Lien WangDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Alexander J LazarDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dominique Knipper-DavisBostonGene Corporation, Waltham, MA 02453, USA.
Amber BerlinskiBostonGene Corporation, Waltham, MA 02453, USA.
Tayla SoaresBostonGene Corporation, Waltham, MA 02453, USA.
Danil StupichevBostonGene Corporation, Waltham, MA 02453, USA.
Kirill KryukovBostonGene Corporation, Waltham, MA 02453, USA.
Suren DavitavyanBostonGene Corporation, Waltham, MA 02453, USA.
Anna NovokreshchenovaBostonGene Corporation, Waltham, MA 02453, USA.
Dmitry LebedevBostonGene Corporation, Waltham, MA 02453, USA.
Stanislav KurpeBostonGene Corporation, Waltham, MA 02453, USA.
Andrey KravetsBostonGene Corporation, Waltham, MA 02453, USA.
Dmitrii BelousovBostonGene Corporation, Waltham, MA 02453, USA.
Michael HensleyBostonGene Corporation, Waltham, MA 02453, USA.
Alexander BagaevBostonGene Corporation, Waltham, MA 02453, USA.
Francesca ParadisoBostonGene Corporation, Waltham, MA 02453, USA.
Vladimir KushnarevBostonGene Corporation, Waltham, MA 02453, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic AlleviationR01CA285454 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Wenbo Li, Pavlos Msaouel · 2024 to 2026
$2.0M
Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal MalignanciesR37CA288448 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pavlos Msaouel · 2024 to 2026
$2.0M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA285454NCI NIH HHS R37 CA288448
6 · The paper itself

Abstract

Renal medullary carcinoma (RMC) is a rare but highly aggressive kidney cancer that resists conventional therapies. To identify therapeutic targets, this study employs histopathologic, genomic, and transcriptomic profiling of 25 RMC samples. TROP2, EPCAM, CLDN6, and CDH6 are significantly overexpressed compared with other renal and solid tumors. Pathway analyses indicate Hippo pathway upregulation and a tumor microenvironment rich in fibroblasts and neutrophils. We subsequently explore treatment of four heavily pretreated patients, all with high TROP2 expression, using sacituzumab govitecan, a TROP2-targeted antibody-drug conjugate. Of these four patients, one patient achieves a partial response with symptom improvement, two patients maintain stable disease, and the median progression-free survival reaches 2.9 months. This study represents the most extensive molecular characterization of RMC to date, identifying TROP2 and other potential therapeutic targets. Sacituzumab govitecan demonstrates potential clinical benefit, warranting further evaluation in prospective trials to confirm its efficacy and explore additional targets identified herein.

Indexed as

Carcinoma, MedullaryCarcinoma, Renal CellGene Expression ProfilingGenomicsKidney NeoplasmsAgedAntibodies, Monoclonal, HumanizedAntigens, NeoplasmCell Adhesion MoleculesFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedTranscriptomeTumor MicroenvironmentAntibodies, Monoclonal, HumanizedAntigens, NeoplasmCell Adhesion MoleculesTACSTD2 protein, humanCDH6CLDN6EPCAMHippo pathwayrenal medullary carcinomasacituzumab govitecanSMARCB1TROP2

Identifiers

PMID41172996
PMCPMC12711661

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.